Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Video

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

While most oncologists have set their sights on targeted therapies or immunotherapy, Oh says it is still the era of chemotherapy in the treatment setting of prostate cancer, as the agent has demonstrated profound benefits when used in newly diagnosed patients with metastatic hormone-sensitive prostate cancer.

The recent positive findings seen with docetaxel come from 2 large randomized trials: CHAARTED from the United States and STAMPEDE from the United Kingdom. In both studies, survival benefits were quite dramatic, according to Oh, reaching as much as 20 months of added benefit in the group of patients who received docetaxel early in the treatment cycle.

Oh says these results are particularly interesting because the agent has already been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) for over a decade. Unfortunately, though, there were multiple negative clinical trials that involved adding another agent to docetaxel in mCRPC. Thus, it came as a bit of a surprise to see that the addition of docetaxel early on led to such benefits.

Oncologists may not be curing these patients, says Oh, but they are delaying disease progression enough to see significant survival benefits.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute